Cardiovascular Adverse Events After Anti-BCMA CAR-T (Ide-Cel and Cilta-Cel) for Relapsed/ Refractory Multiple Myeloma

被引：0
|
作者：
Palfi, Stefanie
Koelmeyer, Himara
Alsina, Melissa
Baz, Rachid
Blue, Brandon
Corallo, Salvatore
De Avila, Gabriel
Freeman, Ciara
Grajales-Cruz, Ariel
Harvey, Kristy
Liu, Hien
Nishihori, Taiga
Oliveira, Guilherme
Oswald, Laura
Puglianini, Omar Castaneda
Shain, Kenneth
Wettenstein, Zachary
Jain, Michael
Locke, Frederick
Alomar, Mohammed
Hansen, Doris
Lee, Dae Hyun
机构：
来源：
CIRCULATION | 2024年 / 150卷
关键词：
D O I：
10.1161/circ.150.suppl_1.4114505
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4114505
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Immunoglobulin isotype switch after anti-BCMA CAR T-cell therapy for relapsed or refractory multiple myeloma
    Liang, Zhiyu
    Li, Ping
    Kang, Liqing
    Zhou, Lili
    Xu, Yang
    Ye, Shiguang
    Du, Juan
    Li, Bing
    Wang, Yiwen
    Yu, Lei
    Qian, Wenbin
    Liang, Aibin
    BLOOD ADVANCES, 2022, 6 (01) : 293 - 296
  • [42] Lenalidomide enhances the efficacy of anti-BCMA CAR-T treatment in relapsed/refractory multiple myeloma: a case report and revies of the literature
    Zhao, Guoxing
    Wei, Runhong
    Feng, Lei
    Wu, Yi
    He, Feng
    Xiao, Mingxing
    Cheng, Zhi
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2022, 71 (01) : 39 - 44
  • [43] KarMMa Subanalysis: Correlation of Baseline Characteristics with Complete Response (CR) to Idecabtagene vicleucel (Ide-Cel, bb2121), a BCMA-Targeted CAR-T Cell Therapy, in Patients with Relapsed and Refractory Multiple Myeloma (RRMM)
    Einsele, H.
    Shah, N.
    Munshi, N.
    Berdeja, J.
    Jagannath, S.
    Finney, O.
    Martin, N.
    Agarwal, A.
    Rowe, E.
    Campbell, T. B.
    San-Miguel, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 248 - 248
  • [44] Humoral immune reconstitution after anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma
    Wang, Ying
    Li, Chunrui
    Xia, Jieyun
    Li, Ping
    Cao, Jiang
    Pan, Bin
    Tan, Xu
    Li, Hujun
    Qi, Kunming
    Wang, Xiangmin
    Shi, Ming
    Jing, Guangjun
    Yan, Zhiling
    Cheng, Hai
    Zhu, Feng
    Sun, Haiying
    Sang, Wei
    Li, Depeng
    Zhang, Xi
    Li, Zhenyu
    Zheng, Junnian
    Liang, Aibin
    Zhou, Jianfeng
    Xu, Kailin
    BLOOD ADVANCES, 2021, 5 (23) : 5290 - 5299
  • [45] Factors Associated with Refractoriness or Early Progression after Idecabtagene Vicleucel (Ide-cel) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): US Myeloma CAR T Consortium Real World Experience
    Hashmi, Hamza
    Hansen, Doris K.
    Peres, Lauren C.
    Puglianini, Omar Alexis Castaneda
    Freeman, Ciara L.
    De Avila, Gabriel
    Sidana, Surbhi
    Shune, Leyla O.
    Sborov, Douglas W.
    Davis, James
    Wagner, Charlotte B.
    Kocoglu, M. Hakan
    Atrash, Shebli
    Voorhees, Peter M.
    Simmons, Gary
    Ferreri, Christopher J.
    Kalariya, Nilesh
    Sannareddy, Aishwarya
    Dima, Danai
    Khouri, Jack
    McGuirk, Joseph P.
    Locke, Frederick L.
    Baz, Rachid C.
    Patel, Krina
    Alsina, Melissa
    BLOOD, 2022, 140 : 4642 - 4645
  • [46] Idecabtagene vicleucel (ide-cel; bb2121); a BCMA-directed CAR T cell therapy; for the treatment of patients with relapsed and refractory multiple myeloma (RRMM): updated results from KarMMa
    Einsele, Hermann
    Anderson, Larry D., Jr.
    Shah, Nina
    Jagannath, Sundar
    Berdeja, Jesus
    Lonial, Sagar
    Raje, Noopur
    Siegel, David S.
    Lin, Yi
    Moreau, Philippe
    Yakoub-Agha, Ibrahim
    Delforge, Michel
    Goldschmidt, Hartmut
    Weisel, Katja
    Cavo, Michele
    Reece, Donna
    Rambaldi, Alessandro
    Truppel-Hartmann, Anna
    Patel, Payal
    Huang, Liping
    Campbell, Timothy B.
    Hege, Kristen
    San-Miguel, Jesus
    Munshi, Nikhil C.
    Oriol, Albert
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 173 - 173
  • [47] Phase II Study of Pembrolizumab in Multiple Myeloma Patients Relapsing after or Refractory to Anti-BCMA CAR-T Therapies
    Chung, Alfred
    Huang, Chiung-Yu
    Martin, Thomas
    Wolf, Jeffrey L.
    Wong, Sandy W.
    Shah, Nina
    BLOOD, 2022, 140 : 12651 - 12652
  • [48] Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeted CAR T-cell therapy, in patients with relapsed and refractory multiple myeloma (RRMM): Initial KarMMa results.
    Munshi, Nikhil C.
    Anderson, Larry D., Jr.
    Shah, Nina
    Jagannath, Sundar
    Berdeja, Jesus G.
    Lonial, Sagar
    Raje, Noopur S.
    Siegel, David Samuel DiCapua
    Lin, Yi
    Oriol, Albert
    Moreau, Philippe
    Yakoub-Agha, Ibrahim
    Delforge, Michel
    Petrocca, Fabio
    Connarn, Jamie
    Patel, Payal
    Huang, Liping
    Campbell, Timothy Brandon
    Hege, Kristen
    San Miguel, Jesus
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [49] A combination of humanized anti-BCMA and murine anti-CD38 CAR-T cell therapy in patients with relapsed or refractory multiple myeloma
    Zhang, Huan
    Liu, Man
    Xiao, Xia
    Lv, Hairong
    Jiang, Yanyu
    Li, Xin
    Yuan, Ting
    Zhao, Mingfeng
    LEUKEMIA & LYMPHOMA, 2022, 63 (06) : 1418 - 1427
  • [50] Pseudoprogression in multiple myeloma patients treated with Anti-BCMA CAR-T cells
    Topp, Max
    Schimanski, Sven
    Hornburger, Hannah
    Kadel, Sophie
    Einsele, Hermann
    Rasche, Leo
    Duell, Johannes
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 146 - 146
12345